BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Industry & Community
Samsung Biologics Bids $1.8 Billion for Swiss Peptide CDMO PolyPeptide Group in Korea's Largest-Ever Pharma Deal
Samsung Biologics launched an all-cash public tender offer of CHF 1.46 billion ($1.8 billion) for Switzerland's PolyPeptide Group on 20 July 2026 — the largest biopharmaceutical M&A transaction in South Korean history. The deal brings a 70-year-old peptide CDMO, six GMP-certified manufacturing sites, and direct exposure to GLP-1 API demand under Samsung Biologics' roof, and signals how urgently global CDMO operators are moving to secure peptide manufacturing capacity ahead of a projected $29…
25 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Shift from Peptide Injections to Small-Molecule Pills Means for the Research Supply Chain
The MHRA approved the first oral GLP-1 tablet for weight loss in June 2026, and the FDA followed with orforglipron (Foundayo) — the first non-peptide small-molecule GLP-1 — in April. Head-to-head trial data now favour the small-molecule entrant on both glycaemic control and weight loss, raising structural questions for peptide API manufacturers and research-grade suppliers about where future demand will concentrate.
25 Jul 2026
Industry & Community
The Macrocyclic Peptide Investment Wave: What Three Major 2026 Deals Signal for the Research Landscape
A cluster of substantial deals in early 2026 — including Novartis's $100 million upfront commitment to Unnatural Products, Syneron Bio's $150 million Series B, and AstraZeneca's ongoing $3.4 billion biobucks arrangement — marks macrocyclic peptides as the modality attracting the most concentrated institutional attention in the peptide space. For research-procurement teams, understanding what distinguishes macrocycles from conventional linear peptides, and why big pharma is now paying platform…
30 May 2026
Industry & Community
Macrocyclic Peptides Draw Wave of Institutional Capital in 2026 as Big Pharma Targets "Undruggable" Biology
A cluster of deals in early 2026 has placed macrocyclic peptides at the centre of pharmaceutical dealmaking, with Syneron Bio closing a $150 million Series B, Novartis committing up to $1.8 billion to Unnatural Products, and AstraZeneca holding a strategic stake in the macrocycle space. For research-procurement teams, the surge signals where institutional confidence in the peptide modality is moving.
15 May 2026